Presentations to be Webcast on September 10 at 3:10 p.m. ET and
September 16 at 9:20 a.m. ET
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
present a brief corporate overview followed by a question and answer
session at the following two investor conferences during the month of
September:
-
September 10, 2015, at 3:10 p.m. ET, Baird 2015 Healthcare Conference
in New York.
-
September 16, 2015 at 9:20 a.m. ET, 2015 Morgan Stanley Global
Healthcare Conference in New York.
A live webcast and replay of the presentation sessions can be accessed
by visiting the “Calendar of Events” section on the “Investors” page of
Enanta’s website at www.enanta.com.
The replay webcasts will be available following the presentations and
will be archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs for viral
infections and liver diseases. Enanta has developed novel protease and
NS5A inhibitors that are members of the direct-acting-antiviral (DAA)
inhibitor classes designed for use against the hepatitis C virus (HCV).
Enanta’s protease inhibitors partnered with AbbVie include paritaprevir,
which is contained in AbbVie’s marketed DAA regimens for HCV, and
ABT-493, Enanta’s next generation protease inhibitor completing phase 2
development. Enanta also has a program to develop a host-targeted
antiviral (HTA) inhibitor class for HCV targeted against cyclophilin, as
well as another DAA program to develop nucleotide polymerase inhibitors.
In addition, Enanta has a preclinical program in non-alcoholic
steatohepatitis, or NASH, which is a condition that results in liver
inflammation and liver damage caused by a buildup of fat in the liver.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150902005094r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150902005094/en/
Copyright Business Wire 2015